Epigenetic therapy in MDS and acute AML: focus on decitabine M. LübbertP. W. Wijermans Preface 17 November 2005 Pages: 1 - 2
Decitabine: a historical review of the development of an epigenetic drug Dick de VosWendy van Overveld Original Article 12 October 2005 Pages: 3 - 8
An epigenetic approach to the treatment of advanced MDS; the experience with the DNA demethylating agent 5-aza-2′-deoxycytidine (decitabine) in 177 patients P. W. WijermansM. LübbertA. Bosly Original Article 07 October 2005 Pages: 9 - 17
Clinical experience with decitabine in North American patients with myelodysplastic syndrome Karen W. L. YeeElias JabbourFrancis J. Giles Original Article 05 November 2005 Pages: 18 - 24
Quantification of outpatient management and hospitalization of patients with high-risk myelodysplastic syndrome treated with low-dose decitabine J. A. PitakoP. S. HaasM. Lübbert Original Article 16 November 2005 Pages: 25 - 31
In vivo effects of decitabine in myelodysplasia and acute myeloid leukemia: review of cytogenetic and molecular studies Björn HackansonChristian RobbelMichael Lübbert Original Article 15 November 2005 Pages: 32 - 38
Clinical implications of aberrant DNA methylation patterns in acute myelogenous leukemia Oliver GalmStefan WilopRainhardt Osieka Original Article 18 October 2005 Pages: 39 - 46
Decitabine activates specific caspases downstream of p73 in myeloid leukemia Ingo TammMandy WagnerKarin Schmelz Original Article 29 September 2005 Pages: 47 - 53
Butyrates and decitabine cooperate to induce histone acetylation and granulocytic maturation of t(8;21) acute myeloid leukemia blasts Antonella GozziniValeria Santini Original Article 15 October 2005 Pages: 54 - 60
Results of a phase 2 study of valproic acid alone or in combination with all-trans retinoic acid in 75 patients with myelodysplastic syndrome and relapsed or refractory acute myeloid leukemia Andrea KuendgenSabine KnippNorbert Gattermann Original Article 04 November 2005 Pages: 61 - 66
The hematopathological basis for studying effects of the demethylating agent 5-aza-2′-deoxycytidine (decitabine) in myelodysplasia Hans Eckart SchaeferMichael Lübbert Original Article 25 November 2005 Pages: 67 - 79
